 |
Top 17 Multiple Sclerosis startups
Oct 12, 2024 | By Jason Kwon | 20 |
These startups develop new Multiple Sclerosis treatments and diagnostics technologies, like AI-powered drug-discovery, gene therapy, stem cells, cerebrospinal fluid analysis, evoked potential testing.
1
Country: USA | Funding: $535.8M
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, multiple sclerosis (MS).
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, multiple sclerosis (MS).
2
Country: USA | Funding: $526.3M
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.
3
Country: USA | Funding: $409M
Pear Therapeutics develops digital therapies to address a broad range of severe conditions including addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and sleep. PEAR’s eFormulationTM platform combines pharmaceutical preparations with user-friendly, customizable, and scientifically validated software applications. PEAR’s patented approach provides better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payors. Pear Therapeutics filed for bankruptcy
Pear Therapeutics develops digital therapies to address a broad range of severe conditions including addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and sleep. PEAR’s eFormulationTM platform combines pharmaceutical preparations with user-friendly, customizable, and scientifically validated software applications. PEAR’s patented approach provides better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payors. Pear Therapeutics filed for bankruptcy
4
Country: Israel | Funding: $210.6M
ReWalk Robotics is an innovative medical device company that is designing, developing and commercializing exoskeletons allowing wheelchair-bound individuals to stand and walk once again. Our mission is to fundamentally change the Quality of Life for individuals with lower limb disability through the creation and development of market leading robotic technologies.
ReWalk Robotics is an innovative medical device company that is designing, developing and commercializing exoskeletons allowing wheelchair-bound individuals to stand and walk once again. Our mission is to fundamentally change the Quality of Life for individuals with lower limb disability through the creation and development of market leading robotic technologies.
5
Country: USA | Funding: $183M
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class that advances programs in multiple sclerosis and psoriasis
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class that advances programs in multiple sclerosis and psoriasis
6
Country: USA | Funding: $135.5M
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
7
Country: USA | Funding: $91M
Octave is a biotechnology company that uses precision medicine and scientific insights to treat patients with multiple sclerosis.
Octave is a biotechnology company that uses precision medicine and scientific insights to treat patients with multiple sclerosis.
8
Country: USA | Funding: $70M
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.
9
Country: Switzerland | Funding: $54.6M
GeNeuro develops innovative treatments against inflammatory and degenerative disorders associated with endogenous retroviruses.
GeNeuro develops innovative treatments against inflammatory and degenerative disorders associated with endogenous retroviruses.
10
Country: USA | Funding: $10.5M
AxoSim's Nerve-on-a-Chip platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
AxoSim's Nerve-on-a-Chip platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
